Paediatric Palliative Formulary 2nd edition published

28th June 2012

The Association for Paediatric Palliative Medicine has published the second edition of its formulary. It has been updated to reflect the recently published World Health Organization guidelines on treating pain in children as well as changes in the use of certain medicines since the publication of the first edition of the formulary in 2011. It can be downloaded from the Together for short lives website link below, or from our document library under the topic of books (paediatric), with grateful thanks to Dr Susie Lapwood (Helen and Douglas House Hospices for children and young adults and Honorary Clinical Fellow, Oxford University Hospitals NHS Trust).

click here to view

Summary of NICE guidance of opioids in palliative care

22nd June 2012

The North West Medicines Information Centre have produced a summary of the key prescribing points from the NICE guidance (CG140) on opioids in palliative care in their monthly bulletin, NICE Bites. 

click here to view

AWMSG recommendations for Buccolam

20th June 2012

The All Wales Medicines Strategy Group (AWMSG) has approved midazolam oromucosal solution 5mg/mL (Buccolam, ViroPharma) as an option for use within NHS Wales for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to <18 years). For infants between 3–6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available. AWMSG state Buccolam should be prescribed by brand name to reduce the risk of medication errors.

click here to view

BNF now available as a free smartphone app

19th June 2012

Health professionals can now access the British National Formulary (BNF) from a smartphone via a new application (app) from the National Institute for Health and Clinical Excellence (NICE). The app requires an NHS Athens username and password and can be run without an internet connection once it has been downloaded.

click here to view

RPS report on the transfer of information about medicines

19th June 2012

A report published by the Royal Pharmaceutical Society (RPS) calls for improvements to the transfer of information about medicines when patients move between care settings and includes several recommendations. The report, Keeping Patients Safe When They Transfer Between Care Providers: Getting the Medicines Right, outlines the results of a 6month project involving over 30 healthcare organisations which volunteered to implement RPS guidance on transfer of medicines information.

click here to view

NICE consultation on denosumab

14th June 2012

The National Institute for Health and Clinical Excellence (NICE) has issued a second appraisal consultation document on the use of denosumab as a treatment to delay or prevent skeletal-related events in people with bone metastases from solid tumours. This follows the committee’s reconsideration of evidence in light of information received during the first consultation. The latest draft guidance makes the following preliminary recommendations:

• denosumab is recommended as an option for preventing skeletal-related events in adults with bone metastases from breast cancer, if the manufacturer provides denosumab with the discount agreed in the patient access scheme

• denosumab is not recommended for preventing skeletal-related events in adults with bone metastases from prostate cancer

• denosumab is recommended as an option for preventing skeletal-related events in adults with bone metastases from solid tumours other than breast and prostate if zoledronic acid or disodium pamidronate would otherwise be prescribed for these patients and the manufacturer provides denosumab with the discount agreed in the patient access scheme

• adults with bone metastases from solid tumours currently receiving denosumab for the prevention of skeletal-related events that is not recommended according to the above, should be able to continue treatment until they and their clinician consider it appropriate to stop.

The consultation period runs until 2 July 2012 and document can be accessed from the link below.

click here to view

Pregabalin oral solution launched in UK

14th June 2012

Pregabalin oral solution 20mg/mL (Lyrica; Pfizer, Sandwich, Kent, UK) has been launched in the UK and is licensed in adults for:

• peripheral and central neuropathic pain
• epilepsy as adjunctive therapy in adults with partial seizures with or without secondary generalisation
• general anxiety disorders.

The NHS cost of a 473mL bottle = £99; 28 days @75mg, 150mg, or 300mg b.d. = £44, £88 and £177 respectively, whereas the oral capsules cost £64 for 28 days treatment at the above doses for all 3 strengths. Pregabalin oral solution has been shown to be bioequivalent to pregabalin capsules.

The Scottish Medicines Consortium (SMC) has accepted pregabalin oral solution for restricted use within NHS Scotland for the following indications in patients who find it difficult to or are unable to swallow tablets:

• patients with peripheral neuropathic pain who have not achieved adequate pain relief from, or have not tolerated, conventional first and second line treatments for peripheral neuropathic pain. Treatment should be stopped if the patient has not shown sufficient benefit within 8 weeks of reaching the maximally tolerated therapeutic dose
• adjunctive therapy in adults with partial seizures with or without secondary generalisation. It should be initiated only by physicians who have appropriate experience in the treatment of epilepsy and should be used principally in patients who have not benefited from treatment with an older anti-convulsant drug such as carbamazepine or sodium valproate, or for whom these drugs are unsuitable because of contra-indications, interaction or poor tolerance.

Pregabalin is not recommended for use in the treatment of generalised anxiety disorder in adults as the company have not made a submission to SMC for use in this indication. For more information see the link below.

SMC product report for pregabalin oral solution

SPC for pregabalin oral solution

click here to view